Last reviewed · How we verify

AMG 386 with or without Trastuzumab

QuantumLeap Healthcare Collaborative · Phase 2 active Small molecule

AMG 386 with or without Trastuzumab is a Angiopoietin-2 inhibitor Small molecule drug developed by QuantumLeap Healthcare Collaborative. It is currently in Phase 2 development for Metastatic breast cancer, HER2-positive. Also known as: AMG 386 (Trebananib); (Trastuzumab) Herceptin.

AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis.

AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis. Used for Metastatic breast cancer, HER2-positive.

At a glance

Generic nameAMG 386 with or without Trastuzumab
Also known asAMG 386 (Trebananib); (Trastuzumab) Herceptin
SponsorQuantumLeap Healthcare Collaborative
Drug classAngiopoietin-2 inhibitor
TargetAngiopoietin-2
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

By inhibiting angiogenesis, AMG 386 aims to reduce the growth of new blood vessels that supply tumors, thereby slowing tumor growth. This mechanism is particularly relevant in the context of cancer treatment, where tumor angiogenesis is a key factor in tumor progression. The addition of Trastuzumab, a monoclonal antibody targeting the HER2 receptor, may enhance the anti-tumor effects of AMG 386 by targeting a different pathway involved in tumor growth and survival.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about AMG 386 with or without Trastuzumab

What is AMG 386 with or without Trastuzumab?

AMG 386 with or without Trastuzumab is a Angiopoietin-2 inhibitor drug developed by QuantumLeap Healthcare Collaborative, indicated for Metastatic breast cancer, HER2-positive.

How does AMG 386 with or without Trastuzumab work?

AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis.

What is AMG 386 with or without Trastuzumab used for?

AMG 386 with or without Trastuzumab is indicated for Metastatic breast cancer, HER2-positive.

Who makes AMG 386 with or without Trastuzumab?

AMG 386 with or without Trastuzumab is developed by QuantumLeap Healthcare Collaborative (see full QuantumLeap Healthcare Collaborative pipeline at /company/quantumleap-healthcare-collaborative).

Is AMG 386 with or without Trastuzumab also known as anything else?

AMG 386 with or without Trastuzumab is also known as AMG 386 (Trebananib); (Trastuzumab) Herceptin.

What drug class is AMG 386 with or without Trastuzumab in?

AMG 386 with or without Trastuzumab belongs to the Angiopoietin-2 inhibitor class. See all Angiopoietin-2 inhibitor drugs at /class/angiopoietin-2-inhibitor.

What development phase is AMG 386 with or without Trastuzumab in?

AMG 386 with or without Trastuzumab is in Phase 2.

What are the side effects of AMG 386 with or without Trastuzumab?

Common side effects of AMG 386 with or without Trastuzumab include Fatigue, Nausea, Diarrhea.

What does AMG 386 with or without Trastuzumab target?

AMG 386 with or without Trastuzumab targets Angiopoietin-2 and is a Angiopoietin-2 inhibitor.

Related